Gritstone bio, Inc.

NasdaqGS:GRTS Stock Report

Market Cap: US$86.5m

Gritstone bio Future Growth

Future criteria checks 2/6

Gritstone bio's earnings are forecast to decline at 0.9% per annum while its annual revenue is expected to grow at 41.1% per year. EPS is expected to grow by 8.7% per annum.

Key information

-0.9%

Earnings growth rate

8.7%

EPS growth rate

Biotechs earnings growth23.1%
Revenue growth rate41.1%
Future return on equityn/a
Analyst coverage

Good

Last updated16 Apr 2024

Recent future growth updates

Recent updates

Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering

Apr 07

Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Aug 14
Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst

Sep 26

Gritstone reaches six-month high on publication of data for cancer vaccine

Aug 16

Gritstone bio announces $80M credit facility

Jul 21

Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?

Jul 07
Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?

Gritstone bio: Potential To Advance Colorectal Cancer Treatment

Jul 05

Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation

Jun 14

Some Analysts Just Cut Their Gritstone bio, Inc. (NASDAQ:GRTS) Estimates

Mar 17
Some Analysts Just Cut Their Gritstone bio, Inc. (NASDAQ:GRTS) Estimates

We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate

Mar 05
We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate

Gritstone: Why The Stock Fell On Positive Data

Jan 18

Gritstone bio (NASDAQ:GRTS) Is In A Strong Position To Grow Its Business

Nov 23
Gritstone bio (NASDAQ:GRTS) Is In A Strong Position To Grow Its Business

Gritstone Poised To Dominate mRNA Market

Nov 08

Here's Why We're Not Too Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Situation

May 26
Here's Why We're Not Too Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Situation

Gritstone Oncology EPS beats by $0.41, beats on revenue

May 06

Earnings and Revenue Growth Forecasts

NasdaqGS:GRTS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202646-183-261N/A3
12/31/202564-132-185-1755
12/31/202436-134-153-1216
12/31/202316-138-126-122N/A
9/30/202310-139-138-133N/A
6/30/202312-130-133-127N/A
3/31/202315-125-128-123N/A
12/31/202220-120-122-116N/A
9/30/202219-118-115-109N/A
6/30/202218-116-105-98N/A
3/31/202216-112-101-95N/A
12/31/202148-75-56-51N/A
9/30/202146-72-57-52N/A
6/30/202145-70-61-57N/A
3/31/202142-71-58-55N/A
12/31/20204-105-93-89N/A
9/30/20204-106-95-86N/A
6/30/20204-107-105-91N/A
3/31/20204-103-104-89N/A
12/31/20194-94-101-85N/A
9/30/20195-84-88-76N/A
6/30/20194-75-56-49N/A
3/31/20193-69-49-42N/A
12/31/20181-65-44-38N/A
9/30/20180-65-46-40N/A
6/30/2018N/A-56-60-49N/A
3/31/2018N/A-47-55-44N/A
12/31/2017N/A-41-46-35N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GRTS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GRTS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GRTS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GRTS's revenue (41.1% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: GRTS's revenue (41.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GRTS's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.